Thrombus formation in inflammatory bowel diseases (IBD): the role of risk factors, markers, diagnostic methods and directions for future research

This article analyzes the pathogenetic mechanisms of thrombus formation in inflammatory bowel diseases (IBD). The main processes leading to the activation of the coagulation cascade are discussed, including chronic inflammation, endothelial dysfunction, and immunomodulatory reactions that contribute to the development of thrombosis. The study pays special attention to risk factors such as genetic predisposition, comorbidities, and features of the pathogenesis of IBD. It also considers the effect of drugs used to treat IBD, including glucocorticosteroids, immunosuppressants, and biological drugs. It evaluates how drug therapy can change thrombus risk profiles and worsen the patient’s prognosis. In addition, the article analyzes modern diagnostic markers, including not only D-dimer, but also microvesicles, microRNA, and many other coagulation indicators. Existing risk assessment scales are presented that facilitate diagnosis and timely adoption of preventive measures. Attention is also drawn to anticoagulant therapy in patients with IBD as an important area for the prevention and treatment of thromboembolic complications. In conclusion, a number of possible directions for future research are proposed aimed at identifying new biomarkers, creating more accurate risk scales, and optimizing treatment strategies for IBD in order to reduce the likelihood of thrombotic complications and improve the quality of life of patients.

Inflammatory bowel disease, thrombosis, chronic inflammation, endothelial dysfunction, IBD treatment, anticoagulant therapy, thromboembolic complications

1. Bernstein C.N., Blanchard J.F., Houston D.S., Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001 Mar;85(3):430-4. PMID: 11307809.

2. Danese S., Papa A., Saibeni S., Repici A., Malesci A., Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol. 2007 Jan;102(1):174-86. doi: 10.1111/j.1572-0241. 2006.00943.x.

3. Yuhara H., Steinmaus C., Corley D.A. Is inflammatory bowel disease an independent risk factor for venous thromboembolism? Gastroenterology. 2013; doi: 10.1053/gast.2013.03.002.

4. Talbot R.W., Heppell J., Dozois R.R., Beart R.W. Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986 Feb;61(2):140-5. doi: 10.1016/s0025-6196(12)65200-8.

5. Andrade M.D., Adriana R. et al. Risk of thrombosis and mortality in inflammatory bowel disease. Clinical and Translational Gastroenterology. 2018; 9:142. doi: 10.1038/s41424-018-0013-8.

6. Alhalabi M. et al. Portal vein thrombosis as extraintestinal complications of Crohn’s disease: a case report and review of literature. Journal of Medical Case Reports. 2024; 18:246. doi: 10.1186/s13256-024-04560-w.

7. Kappelman M.D., Horvath-Puho E., Sandler R.S. et al. Association of inflammatory bowel disease with venous thromboembolism. Gastroenterology. 2011. doi: 10.1053/gast.2010.10.045.

8. Nguyen G.C., Sam J., Anand N. Increased risk of venous thromboembolism in ulcerative colitis and Crohn's disease. Am J Gastroenterol. 2010. doi: 10.1038/ajg.2010.96.

9. Danese S., Roda G., Peyrin-Biroulet L. et al. Inflammatory bowel disease: a risk factor for venous thromboembolism? Lancet. 2007. doi: 10.1016/S0140-6736(07)61493-5.

10. Saleh T., Fisher A., Lasher M. Vascular complications in inflammatory bowel disease. J Gastrointest Surg. 2012. doi: 10.1007/s11605-011-1734-6.

11. Williet N., Barreau F., Bessis G. Biomarkers in inflammatory bowel disease: therapeutic implications. Curr Opin Gastroenterol. 2016. doi: 10.1097/MOG.0000000000000306.

12. Zitomersky N.L., Verhave M., Trenor C.C. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis. 2011;17(1):458-70. doi: 10.1002/ibd.21334.

13. Katsanos A.H., Kosmidou M., Giannopoulos S. et al. Cerebral arterial infarction in inflammatory bowel diseases. Eur J Intern Med. 2014; 25:37-44. doi: 10.1016/j.ejim.2013.08.702.

14. Schneiderman J.H., Sharpe J.A., Sutton D.M. Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol. 1979; 5: 331-37. doi: 10.1002/ana.410050405.

15. Keyser B.J., Hass A.N. Retinal vascular disease in ulcerative colitis. Am J Ophthalmol. 1994; 118: 395-96. doi: 10.1016/s0002-9394(14)72968-x.

16. Vayalambrone D., Ivanova T., Misra A. Nonischemic central retinal vein occlusion in an adolescent patient with ulcerative colitis. Case Rep. Ophthalmol Med. 2011; 963583. doi: 10.1155/2011/963583.

17. Joshi D., Dickel, T., Aga, R. et al. Stroke in inflammatory bowel disease: a report of two cases and review of the literature. Thrombosis J. 2008; 6:(2). doi: 10.1186/1477-9560-6-2.

18. Burke K.E., Bouges S., Freeman H.J. Advances in the management of thromboembolism in IBD. Nat Rev Gastroenterol Hepatol. 2021. doi: 10.1038/s41575-021-00473-9.

19. Mehta P., Mahajan S., Yadav V.K. Emerging therapies in IBD: Beyond TNF inhibitors. Gastroenterology. 2020; doi: 10.1053/j.gastro.2020.03.039.

20. Sands B.E., Kaplan G.G., Almario C.V. New perspectives on thrombosis in IBD. Gastroenterology. 2021. doi: 10.1053/j.gastro.2021.03.003.

21. Fiorino G., Morar P., Bombardieri M. Biomarkers in IBD-associated thrombosis. Lancet Gastroenterol Hepatol. 2019. doi: 10.1016/S2468-1253(19)30017-6.

22. Loftus E.V., Kane S.V., Sandborn W.J. Predicting complications in IBD. Am J Gastroenterol. 2012. doi: 10.1038/ajg.2012.78.

23. Cheng K., Faye A.S. Venous thromboembolism in inflammatory bowel disease. World J Gastroenterol. 2020; 26(12): 1231-1241. doi: 10.3748/wjg.v26.i12.1231.

24. Colombel J.F., Narula N., Peyrin-Biroulet L. Management strategies to prevent complications in IBD. Clinical Gastroenterology and Hepatology. 2016. doi: 10.1016/j.cgh.2016.01.020.

25. Joshi D., Dickel, T., Aga, R. et al. Stroke in inflammatory bowel disease: a report of two cases and review of the literature. Thrombosis J. 2008; 6(2). doi: 10.1186/1477-9560-6-2.

26. Seo G.S., Chae S.C. Biological therapy for ulcerative colitis: An update. World J Gastroenterol. 2014; 20(37): 13234-13238. doi: 10.1002/ibd.24567.

27. Gilreath M., Patel N.C., Suh J., Brill J.V. Gastroenterology Physician Practice Management and Private Equity: Thriving in Uncertain Times. Clin Gastroenterol Hepatol. 2021; 19(6): 1084-1087. doi: 10.1016/j.cgh.2021.03.015.

28. Lopez-Olivo M.A., Tayar J.H., Martinez-Lopez J.A. et al. Risk of venous thromboembolism in patients with rheumatoid arthritis receiving biologic agents: a systematic review and meta-analysis. Arthritis Rheumatol. 2014;66(12):3013-3021. doi: 10.1002/art.38714.

29. Yao H., Sokas C., Welch H.G. Rising Incidence of Cancer of the Small Intestine: Overdiagnosis and Better Diagnosis of Low-lethality Disease. Gastroenterology. 2022;162(6):1749-1751. doi: 10.1053/j.gastro.2022.01.012.

30. Giannotta M., Tapete G. et al. Thrombosis in inflammatory bowel diseases: what’s the link? Thrombosis Journal. 2015; 13-14. doi: 10.1186/s12959-015-0044-2.

31. Papa A. et al. Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. World Journal of Gastroenterology. WJG. 2014; 20(12):3173. doi: 10.3748/wjg.v20.i12.3173.

32. Severinsen M.T., Kristensen S.R. et al. Venous thromboembolism and risk of cancer in patients with inflammatory bowel disease. Lancet. 2011; doi: 10.1016/S0140-6736(10)60965-4.

33. Barreiro-de Acosta M., Vallejo N. et al. Evaluation of thrombin generation in inflammatory bowel disease using calibrated automated thrombography. Thromb Res. 2016. doi: 10.1016/j.thromres.2016.01.011.

34. Carter M.J., Lobo A.J., Travis S.P.L. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53(5):1-16. doi: 10.1136/gut.2003.036285.

35. Knyazev O.V., Kagramanova A.V., Lishchinskaya A.A., Li I.A. et al. Efficacy and safety of dual therapy - biological and small molecules in patients with ulcerative colitis. Experimental and Clinical Gastroenterology. 2023;217(9): 5-12. (In Russ.) doi: 10.31146/1682-8658-ecg-217-9-5-12.@@ Князев О.В., Каграманова А.В., Лищинская А.А., Ли И.А., и др. Эффективность и безопасность двойной терапии - биологической и малыми молекулами у пациентов с язвенным колитом. Экспериментальная и клиническая гастроэнтерология. 2023;217(9): 5-12. doi: 10.31146/1682-8658-ecg-217-9-5-12.

36. Goessens L., Colombel J.F., Outtier A. et al. European COMBIO study group; Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. United European Gastroenterol J. 2021;9(10):1136-1147. doi: 10.1002/ueg2.12170.

37. Yoshida T., Shimizu H., Hamamoto J. Emerging strategies in IBD management. Clin Gastroenterol Hepatol. 2017. doi: 10.1016/j.cgh.2016.12.027.

38. Baumgart D.C., Carding S.R. Inflammatory bowel disease: cause and immune response. Lancet. 2007. doi: 10.1016/S0140-6736(07)60689-0.

39. Scharl M., Weber A., Frei P. Thromboembolic events in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016; doi: 10.1016/j.cgh.2016.02.003.

40. Ardizzone S., Bollani S., Manzionna G. Inflammatory bowel disease and thromboembolism. World J Gastroenterol. 2008. doi: 10.3748/wjg.v14.i4.415.

41. Andersen N.N., Pasternak B., Basit S. Risk of venous thromboembolism in patients with inflammatory bowel disease. J Crohns Colitis. 2015. doi: 10.1016/j.crohns.2015.01.022.

42. Heit J.A., Silverstein M.D., Mohr D.N. Venous thromboembolism risk in inflammatory bowel disease. Blood. 2002. doi: 10.1182/blood-2002-01-0036.

43. Kappelman M.D., Horvath-Puho E., Sandler R.S. et al. Association of inflammatory bowel disease with venous thromboembolism. Gastroenterology. 2011. doi: 10.1053/gast.2010.10.045.

44. Deban L., Correale C., Vetrano S. et al. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: A Jack of all trades. Am J Pathol. 2008;172(6):1457-66. doi: 10.2353/ajpath.2008.070593.

45. Talbot R. W. et al. Vascular complications of inflammatory bowel disease. Mayo Clinic Proceedings. Elsevier. 1986; 61(2): 140-145. doi: 10.1016/j.mayocp.1986.02.012.

46. Koutroubakis I.E., Tsiolakidou G. et al. The relationship between coagulation and inflammatory markers in active and quiescent inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2008; doi: 10.1097/01.meg.0000311258.85349.13.

47. Ungaro R.C., Chang H.L., Cote-Daigneault J. et al. Risk of venous thromboembolism in patients with inflammatory bowel diseases. Lancet Gastroenterol Hepatol. 2020; doi: 10.1016/S2468-1253(19)30411-4.

48. Papa A. et al. Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. World Journal of Gastroenterology. WJG. 2014; 20(12):3173. doi: 10.3748/wjg.v20.i12.3173.

49. Severinsen M.T., Kristensen S.R. et al. Venous thromboembolism and risk of cancer in patients with inflammatory bowel disease. Lancet. 2011. doi: 10.1016/S0140-6736(10)60965-4.

50. Nelson A.D., Fluxá D., Caldera F. et al. Thromboembolic Events in Hospitalized Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2023;68(6):2597-2603. doi: 10.1007/s10620-023-07920-6.

51. Greywoode R., Larson J. et al. Risk of Adverse Cardiovascular Outcomes in Postmenopausal Women with Inflammatory Bowel Disease. Digestive Diseases and Sciences. 2024; 69:2586-2594. doi: 10.1007/s10620-024-08348-2.

52. Guliaikhina D.E. The effect of warfarin, heparin and new oral anticoagulants (dabigatran etexilate, rivaroxaban, apixaban) on the level of coagulation factors: V, VII, VIII, IX, XII, WF. Bulletin of the North-Western State Medical University named after. I.I. Mechnikov. 2019; Т. 11(1): 79-92. (In Russ.) doi: 10.17816/mechnikov201911179-92.@@ Гуляихина Д.Е. Влияние варфарина, гепарина и новых пероральных прямых антикоагулянтов (дабигатрана этексилата, ривароксабана, апиксабана) на уровень факторов свертывания: V, VII, VIII, IX, XII, WF. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2019; Т. 11(1): 79-92. doi: 10.17816/mechnikov201911179-92.

53. Bauersachs R., Berkowitz S.D., Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. NEJM. 2010; doi: 10.1056/NEJMoa1007903.

54. Raskob G.E., van Es N., Verhamme P. et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. NEJM. 2018; doi: 10.1056/NEJMoa1711948.

55. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEJM. 2009; doi: 10.1056/NEJMoa0905561.

56. Bargen J., Barker N.W. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch Intern Med. 1936; 58:17-31. doi: 10.1001/archinte.1936.00170110025002.

57. Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. NEJM. 2009. doi: 10.1056/NEJMoa0906598.

58. Seo G.S., Chae S.C. Biological therapy for ulcerative colitis: An update. World J Gastroenterol. 2014; 20(37): 13234-13238. doi: 10.1002/ibd.24567.

59. Weitz J.I., Lensing A.W., Prins M.H. et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. NEJM. 2017; 376(13):1211-1222. doi: 10.1056/NEJMoa1700518.

60. Eikelboom J.W., Connolly S.J., Bosch J. et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. NEJM. 2017; 377:1319-1330. doi: 10.1056/NEJMoa1709118.

61. Agnelli G., Buller H.R., Cohen A. et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. NEJM.2013; doi: 10.1056/NEJMoa1302507.

62. Meldo A.A., Utkin L.V., Trofimova T.N. Artificialintel- ligence in medicine: current state and main directions of development of intellectual diagnostics. Radiation diagnostics and therapy. 2020;11(1):9-17. (In Russ.) doi: 10.22328/2079-5343-2020-11-1-9-17@@ Мелдо А.А., Уткин Л.В., Трофимова Т.Н. Искусственный интеллект в медицине: современное состояние и основные направления развития интеллектуальной диагностики. Лучевая диагностика и терапия. 2020;11(1):9-17. doi: 10.22328/2079-5343-2020-11-1-9-17.

63. Guliyeva A.A. Development of artificial intelligence based on neural networks. Actual research. 2022;34(113):6-9. (In Russ.)@@ Гулиева А.А. Развитие искусственного интеллекта на основе нейронных сетей. Актуальные исследования. 2022;34(113):6-9.

64. Uspenskiy Yu. P., Ivanov S.V., Fominykh Yu. A., Narkevich A.N., Grjibovski A.M., Segal’ A.M. Prediction of life-threatening complications of inflammatory bowel disease using neural networks: a practical tool for health care professionals. Experimental and Clinical Gastroenterology. 2023;217(9): 20-33. (In Russ.) doi: 10.31146/1682-8658-ecg-217-9-20-33.@@ Успенский Ю. П., Иванов С.В., Фоминых Ю.А., Наркевич А.Н., Сегаль А.М., Гржибовский А.М. Прогнозирование развития жизнеугрожающих осложнений воспалительных заболеваний кишечника с использованием нейронных сетей: инструменты для практического здравоохранения. Экспериментальная и клиническая гастроэнтерология. 2023;217(9): 20-33. doi: 10.31146/1682-8658-ecg-217-9-20-33.

65. Lishchinskaia A.A., Kagramanova A.V. et al. Thromboembolic complications in patients with inflammatory bowel diseases. Farmateka. 2019;26(2):10-19. (In Russ) doi: 10.18565/pharmateca.2019.2.10-19.@@ Лищинская А.А., Каграманова А.В. и др. Тромбоэмболические осложнения у пациентов с воспалительными заболеваниями кишечника. Фарматека. 2019; 26(2):10-19. (In Russ.) doi: 10.18565/pharmateca.2019.2.10-19.